Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Lexeo Therapeutics, Inc. (LXEO) had Consolidated Net Income/Loss of $-20.92M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-20.92M |
|
-- |
|
-- |
|
$23.12M |
|
$-23.12M |
|
$2.20M |
|
$-20.92M |
|
$-20.92M |
|
$-20.92M |
|
$-20.92M |
|
|
Consolidated Net Income/Loss |
$-20.92M |
$-20.92M |
|
$-23.12M |
|
$-23.04M |
|
53.65M |
|
53.65M |
|
$0.06 |
|
$0.06 |
|
| Balance Sheet Financials | |
$188.39M |
|
$1.14M |
|
$80.30M |
|
$268.69M |
|
$16.81M |
|
$0.33M |
|
$5.21M |
|
$22.02M |
|
$246.67M |
|
$246.67M |
|
$246.67M |
|
73.00M |
|
| Cash Flow Statement Financials | |
$-98.56M |
|
$-90.25M |
|
$216.79M |
|
$38.27M |
|
$66.25M |
|
$27.98M |
|
$12.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.21 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-98.96M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.48% |
|
-8.48% |
|
-7.79% |
|
-8.47% |
|
$3.38 |
|
$-1.84 |
|
$-1.84 |
|